These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 1501691)

  • 1. MPTP toxicity and the "biochemical" blood-brain barrier.
    Harik SI
    NIDA Res Monogr; 1992; 120():43-53. PubMed ID: 1501691
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies.
    Harik SI; Riachi NJ; Hritz MA; Berridge MS; Sayre LM
    J Pharmacol Exp Ther; 1993 Aug; 266(2):790-5. PubMed ID: 8355208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline.
    Ogunrombi MO; Malan SF; Terre'Blanche G; Castagnoli K; Castagnoli N; Bergh JJ; Petzer JP
    Life Sci; 2007 Jul; 81(6):458-67. PubMed ID: 17655878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice.
    Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
    J Pharmacol Exp Ther; 1991 May; 257(2):691-7. PubMed ID: 2033514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Kinetic characteristics of monoamine oxidase in brain regions of animals with varying degrees of sensitivity to 1-methyl, 4-phenyl, 1,2,3,6- tetrahydropyridine].
    Ishkov AG; Ermakov NV; Mikerov SV; Miroshnichenko EV
    Vopr Med Khim; 1991; 37(5):49-52. PubMed ID: 1759397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain.
    Riachi NJ; LaManna JC; Harik SI
    J Pharmacol Exp Ther; 1989 Jun; 249(3):744-8. PubMed ID: 2786562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) binding sites in C57BL/6 mouse brain: mutual effects of monoamine oxidase inhibitors and sigma ligands on MPTP and sigma binding sites.
    Itzhak Y; Mash D; Zhang SH; Stein I
    Mol Pharmacol; 1991 Mar; 39(3):385-93. PubMed ID: 1848660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration.
    Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1000-7. PubMed ID: 7932147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
    Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G
    Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons.
    McKinley ET; Baranowski TC; Blavo DO; Cato C; Doan TN; Rubinstein AL
    Brain Res Mol Brain Res; 2005 Nov; 141(2):128-37. PubMed ID: 16209898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes.
    Di Monte DA; Wu EY; Delanney LE; Irwin I; Langston JW
    J Pharmacol Exp Ther; 1992 Apr; 261(1):44-9. PubMed ID: 1560384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium.
    Giovanni A; Sonsalla PK; Heikkila RE
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1008-14. PubMed ID: 7932148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver.
    Riachi NJ; Harik SI; Kalaria RN; Sayre LM
    J Pharmacol Exp Ther; 1988 Feb; 244(2):443-8. PubMed ID: 3258032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of internal carotid administration of MPTP on rat brain and blood-brain barrier.
    Riachi NJ; Dietrich WD; Harik SI
    Brain Res; 1990 Nov; 533(1):6-14. PubMed ID: 2085733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of MAO in MPTP toxicity--a review.
    Glover V; Gibb C; Sandler M
    J Neural Transm Suppl; 1986; 20():65-76. PubMed ID: 3091762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A reactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is formed in rat brain in vitro by type B monoamine oxidase.
    Corsini GU; Pintus S; Bocchetta A; Piccardi MP; Del Zompo M
    J Pharmacol Exp Ther; 1986 Aug; 238(2):648-52. PubMed ID: 3488394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes.
    Di Monte DA; Wu EY; Irwin I; Delanney LE; Langston JW
    J Pharmacol Exp Ther; 1991 Aug; 258(2):594-600. PubMed ID: 1907660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs.
    Youngster SK; Sonsalla PK; Sieber BA; Heikkila RE
    J Pharmacol Exp Ther; 1989 Jun; 249(3):820-8. PubMed ID: 2786564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
    Coleman T; Ellis SW; Martin IJ; Lennard MS; Tucker GT
    J Pharmacol Exp Ther; 1996 May; 277(2):685-90. PubMed ID: 8627546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.